Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 10/25 10:00:00 pm
74.41 USD   +0.35%
10/25 GILEAD SCIENCES : to Release Third Quarter 2016 Financial Results on..
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/24 GILEAD SCIENCES : to Present at the Credit Suisse 25th Annual Health..
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
05/11/2012 | 09:06pm CEST
   By Jennifer Corbett Dooren 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
10/25 GILEAD SCIENCES : to Release Third Quarter 2016 Financial Results on Tuesday, No..
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/24 GILEAD SCIENCES : to Present at the Credit Suisse 25th Annual Healthcare Confere..
10/24 GILEAD SCIENCES : Presents Results from Phase 3 Studies Evaluating Switching to ..
10/20 GILEAD SCIENCES : Patent Issued for Methods of Treating Patients Co-Infected wit..
10/20 GILEAD SCIENCES : Jolley Asset Management buys $3,491,855 stake in Gilead Scienc..
10/20 GILEAD SCIENCES : Announces SVR12 Rates From Four Phase 3 Studies of a Once-Dail..
10/20 GILEAD SCIENCES : Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) i..
10/14 GILEAD SCIENCES : Creative Planning buys $25,314,133 stake in Gilead Sciences
10/10 GILEAD SCIENCES : Private Asset Management Inc buys $8,511,601 stake in Gilead S..
More news
Sector news : Bio Therapeutic Drugs
10/21DJU.S. HOT STOCKS : Hot Stocks to Watch
10/20DJALKERMES : Shares Surge
10/20 ACTELION : raises guidance for third time this year on strong PAH sales
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
10/25 Best And Worst Performing Stocks 2016 YTD
10/24 Cheap Stocks Vs. Value Traps - Update And Watchlist
10/24 Manic Monday Markets - Propped Up Futures Give Us Another Opportunity
10/24 BIOTECH FORUM DAILY DIGEST : Election Worries Overblown? Spotlight On Akorn
10/21 BEST NEAR-TERM PRICE GAINS AHEAD FOR : Established Biotechnology Stocks
Financials ($)
Sales 2016 30 322 M
EBIT 2016 20 094 M
Net income 2016 14 611 M
Debt 2016 2 884 M
Yield 2016 2,49%
P/E ratio 2016 6,97
P/E ratio 2017 6,67
EV / Sales 2016 3,33x
EV / Sales 2017 3,30x
Capitalization 98 196 M
More Financials
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 103 $
Spread / Average Target 38%
Consensus details
EPS Revisions
More Estimates Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-26.47%97 853
AMGEN, INC.-2.73%118 810
ACTELION LTD3.65%15 677
More Results